Johnson & Johnson (JNJ.US) Q3 earnings exceed expectations and full-year guidance is raised! Innovative pharmaceuticals business expands, while medical device segment still needs improvement

```htmlAccording to Golden Ten Data APP, before the U.S. stock market opened on Tuesday, Johnson & Johnson (JNJ.US) announced better-than-expected results for Q3 2026 and raised its full-year revenue and profit guidance for 2026. The financial report shows Johnson & Johnson’s third-quarter sales increased by 5.9% year-on-year to USD 25.4 billion, matching market expectations. On the profit front, net profit under GAAP fell sharply by 95.9% year-on-year to USD 210 million, with diluted earnings per share at only USD 0.09 (compared to USD 2.12 a year earlier), mainly due to a one-off pre-tax charge of USD 5.519 billion related to a proposed resolution for talcum powder litigations.```